Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Humacyte, Inc. (HUMA : NSDQ)

• Company Description    Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C. Number of Employees: 164

• Price / Volume Information    Yesterday's Closing Price: $3.38 Daily Weekly Monthly 20 Day Moving Average: 361,243 shares Shares Outstanding: 103.33 (millions) Market Capitalization: $349.25 (millions) Beta: 1.22 52 Week High: $6.38 52 Week Low: $1.96 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -23.18% -26.09% 12 Week 18.60% 10.09% Year To Date 60.19% 45.71%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2525 EAST NORTH CAROLINA HIGHWAY 54 - DURHAM,NC 27713 USA ph: 919-313-9633 fax: - investors@humacyte.com http://www.humacyte.com

• General Corporate Information    Officers Laura E. Niklason - President; Chief Executive Officer and Director Dale A. Sander - Chief Financial Officer; Chief Corporate Developme Kathleen Sebelius - Director Gordon M. Binder - Director Emery N. Brown - Director Peer Information Humacyte, Inc. (CORR.) Humacyte, Inc. (RSPI) Humacyte, Inc. (CGXP) Humacyte, Inc. (BGEN) Humacyte, Inc. (GTBP) Humacyte, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 44486Q103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/11/23 Share - Related Items Shares Outstanding: 103.33 Most Recent Split Date: (:1) Beta: 1.22 Market Capitalization: $349.25 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.22 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.86 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.27 Price/Cash Flow: - Price / Sales: 200.49 EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: -4.76% Sales Growth vs. Year Ago Period: -87.14% vs. Previous Quarter: -97.62% ROE 03/31/23 - -76.90 12/31/22 - -73.64 09/30/22 - -74.59 ROA 03/31/23 - -41.12 12/31/22 - -37.69 09/30/22 - -35.49 Current Ratio 03/31/23 - 5.67 12/31/22 - 7.88 09/30/22 - 9.75 Quick Ratio 03/31/23 - 5.67 12/31/22 - 7.88 09/30/22 - 9.75 Operating Margin 03/31/23 - - 12/31/22 - - 09/30/22 - -5,212.92 Net Margin 03/31/23 - - 12/31/22 - - 09/30/22 - 1,971.30 Pre-Tax Margin 03/31/23 - -2,184.83 12/31/22 - -764.54 09/30/22 - 1,971.30 Book Value 03/31/23 - 0.79 12/31/22 - 1.13 09/30/22 - 1.15 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - 0.42 12/31/22 - 0.34 09/30/22 - 0.37 Debt-to-Capital 03/31/23 - 29.74 12/31/22 - 25.10 09/30/22 - 26.93

Powered by Zacks Investment Research ©